Exome Asset Management LLC
13F Reported Value
ⓘ$162.1M
Holdings
52
Latest Filing
2026-06-30
Filing Quarter
Q2 2026
Portfolio Overview
Exome Asset Management LLC disclosed 52 positions worth $162.1M in its Form 13F-HR for Q2 2026, led by $GH (Guardant Health, Inc.) at 6.3% of the equity portfolio, followed by $PRAX and $TGTX. During the quarter the fund opened 15 new positions and exited 19 — including a new stake in $TGTX. The portfolio is most concentrated in Healthcare (97.6% of disclosed assets). All figures are sourced directly from Exome Asset Management LLC’s Form 13F-HR filing with the SEC under CIK 2011932.
AI Fund Analysis
DiversifyingSector Allocation
AUM History
Top Equity Holdings by Value
Quarterly Activity — Q2 2026
Click any card to unlockTop Holdings
- 39.0#2,164
Quality
$10.1M67,500 sh - $9.1M27,205 sh
- 69.3#276
Quality
$9.1M164,915 sh - —
Quality
$8.1M210,523 sh - 23.4
Quality
$7.0M88,177 sh - 87.5
Quality
$6.6M5,492 sh - —
Quality
$6.2M46,878 sh - 7.1
Quality
$5.8M204,418 sh - 28.1
Quality
$5.1M60,056 sh - —
Quality
$5.1M100,203 sh
| Company | Quality | Value | Shares |
|---|---|---|---|
 Guardant Health, Inc.$GH | 39.0#2,164 | $10.1M | 67,500 |
 Praxis Precision Medicines, Inc.$PRAX | — | $9.1M | 27,205 |
 TG THERAPEUTICS, INC.$TGTX | 69.3#276 | $9.1M | 164,915 |
 Cogent Biosciences, Inc.$COGT | — | $8.1M | 210,523 |
 IONIS PHARMACEUTICALS INC$IONS | 23.4 | $7.0M | 88,177 |
 ELI LILLY & Co$LLY | 87.5 | $6.6M | 5,492 |
 Abivax S.A.$ABVX | — | $6.2M | 46,878 |
 ALUMIS INC.$ALMS | 7.1 | $5.8M | 204,418 |
 CYTOKINETICS INC$CYTK | 28.1 | $5.1M | 60,056 |
 Enliven Therapeutics, Inc.$ELVN | — | $5.1M | 100,203 |
Unlock AI quality scores for every holding
32-signal composite ranking on each of Exome Asset Management LLC's 52 positions.
Showing top 10 of 52 holdings.
Sector Allocation
Healthcare
$158.2M
Technology
$3.9M
Full Holdings — Exome Asset Management LLC (Q2 2026)
All 52 disclosed positions from the latest Form 13F-HR, with quarter-over-quarter share changes and 13F Pro quality scores. Sourced from SEC EDGAR.
| # | Ticker | Company | Value | Weight | QoQ | Quality |
|---|---|---|---|---|---|---|
| 1 | $GH | Guardant Health, Inc. | $10.1M | 6.3% | -18% | 39 |
| 2 | $PRAX | Praxis Precision Medicines, Inc. | $9.1M | 5.6% | -40% | — |
| 3 | $TGTX | TG THERAPEUTICS, INC. | $9.1M | 5.6% | NEW | 69.3 |
| 4 | $COGT | Cogent Biosciences, Inc. | $8.1M | 5.0% | -24% | — |
| 5 | $IONS | IONIS PHARMACEUTICALS INC | $7.0M | 4.3% | -20% | 23.4 |
| 6 | $LLY | ELI LILLY & Co | $6.6M | 4.1% | -22% | 87.5 |
| 7 | $ABVX | Abivax S.A. | $6.2M | 3.9% | NEW | — |
| 8 | $ALMS | ALUMIS INC. | $5.8M | 3.5% | -27% | 7.1 |
| 9 | $CYTK | CYTOKINETICS INC | $5.1M | 3.2% | -42% | 28.1 |
| 10 | $ELVN | Enliven Therapeutics, Inc. | $5.1M | 3.1% | -54% | — |
| 11 |  $VERA | Vera Therapeutics, Inc. | $4.2M | 2.6% | -15% | — |
| 12 |  $UNH | UNITEDHEALTH GROUP INC | $4.0M | 2.5% | -25% | 62.7 |
| 13 |  $TXG | 10x Genomics, Inc. | $3.9M | 2.4% | -33% | 40.5 |
| 14 |  $NTRA | Natera, Inc. | $3.7M | 2.3% | -26% | 53.5 |
| 15 |  $QURE | uniQure N.V. | $3.7M | 2.3% | NEW | — |
| 16 |  $RYTM | RHYTHM PHARMACEUTICALS, INC. | $3.6M | 2.2% | -21% | 33.9 |
| 17 |  $MAZE | Maze Therapeutics, Inc. | $3.4M | 2.1% | +30% | 10.3 |
| 18 |  $GLUE | Monte Rosa Therapeutics, Inc. | $3.3M | 2.0% | -24% | 30.3 |
| 19 |  $MLTX | MoonLake Immunotherapeutics | $3.2M | 2.0% | -23% | — |
| 20 |  $ALKS | Alkermes plc. | $3.2M | 2.0% | -27% | — |
| 21 |  $LQDA | Liquidia Corp | $3.1M | 1.9% | -14% | 78.3 |
| 22 |  $UTHR | UNITED THERAPEUTICS Corp | $2.9M | 1.8% | -23% | 71.3 |
| 23 |  $GKOS | GLAUKOS Corp | $2.8M | 1.7% | -5% | 40.5 |
| 24 |  $ARWR | ARROWHEAD PHARMACEUTICALS, INC. | $2.6M | 1.6% | -30% | 38.7 |
| 25 |  $AGIO | AGIOS PHARMACEUTICALS, INC. | $2.6M | 1.6% | -44% | 26.9 |
| 26 |  $CBIO | CRESCENT BIOPHARMA, INC. | $2.3M | 1.4% | -17% | 9.6 |
| 27 |  $AZN | ASTRAZENECA PLC | $2.3M | 1.4% | NEW | — |
| 28 |  $BSX | BOSTON SCIENTIFIC CORP | $2.1M | 1.3% | +0% | 77.5 |
| 29 |  $ADAG | Adagene Inc. | $2.1M | 1.3% | -34% | — |
| 30 |  $PEN | Penumbra Inc | $2.0M | 1.2% | +0% | 67.1 |
| 31 |  $ISRG | INTUITIVE SURGICAL INC | $2.0M | 1.2% | -23% | 79.9 |
| 32 |  $VKTX | Viking Therapeutics, Inc. | $1.9M | 1.1% | NEW | — |
| 33 |  $OCUL | OCULAR THERAPEUTIX, INC | $1.8M | 1.1% | NEW | 8.4 |
| 34 |  $EQ | Equillium, Inc. | $1.8M | 1.1% | NEW | 11.7 |
| 35 |  $ASND | Ascendis Pharma A/S | $1.8M | 1.1% | NEW | 44.8 |
| 36 |  $CRBP | Corbus Pharmaceuticals Holdings, Inc. | $1.7M | 1.1% | -21% | — |
| 37 |  $CTMX | CytomX Therapeutics, Inc. | $1.7M | 1.1% | -12% | 8.7 |
| 38 |  $VSTM | Verastem, Inc. | $1.6M | 1.0% | -33% | 29.7 |
| 39 |  $NKTR | NEKTAR THERAPEUTICS | $1.6M | 1.0% | NEW | 9.7 |
| 40 |  $CLPT | ClearPoint Neuro, Inc. | $1.5M | 0.9% | NEW | 26.1 |
| 41 |  $INSM | INSMED Inc | $1.5M | 0.9% | -48% | 39.4 |
| 42 |  $CAI | Caris Life Sciences, Inc. | $1.4M | 0.9% | NEW | 69 |
| 43 |  $BBIO | BridgeBio Pharma, Inc. | $1.4M | 0.8% | -73% | 36.9 |
| 44 |  $ZBIO | Zenas BioPharma, Inc. | $1.3M | 0.8% | -35% | 7.4 |
| 45 |  $NBP | NovaBridge Biosciences | $1.1M | 0.7% | +0% | — |
| 46 |  $ESTA | ESTABLISHMENT LABS HOLDINGS INC. | $1.1M | 0.7% | +0% | 33.9 |
| 47 |  $RLAY | Relay Therapeutics, Inc. | $889,305 | 0.6% | -83% | 19.5 |
| 48 |  $GERN | GERON CORP | $798,779 | 0.5% | NEW | — |
| 49 |  $DRUG | BRIGHT MINDS BIOSCIENCES INC. | $709,722 | 0.4% | NEW | — |
| 50 |  $CMPX | Compass Therapeutics, Inc. | $604,801 | 0.4% | NEW | 28.1 |
| 51 |  $REPL | Replimune Group, Inc. | $446,796 | 0.3% | NEW | — |
| 52 |  $ABUS | Arbutus Biopharma Corp | $240,797 | 0.1% | -34% | 7.3 |
New Positions (15)
$TGTX TG THERAPEUTICS, INC.$9.1M$ABVX Abivax S.A.$6.2M$QURE uniQure N.V.$3.7M$AZN ASTRAZENECA PLC$2.3M$VKTX Viking Therapeutics, Inc.$1.9M$OCUL OCULAR THERAPEUTIX, INC$1.8M$EQ Equillium, Inc.$1.8M$ASND Ascendis Pharma A/S$1.8M$NKTR NEKTAR THERAPEUTICS$1.6M$CLPT ClearPoint Neuro, Inc.$1.5M$CAI Caris Life Sciences, Inc.$1.4M$GERN GERON CORP$798,779$DRUG BRIGHT MINDS BIOSCIENCES INC.$709,722$CMPX Compass Therapeutics, Inc.$604,801$REPL Replimune Group, Inc.$446,796Exited Positions (19)
$ELV Elevance Health, Inc.$CYTKPUT CYTOKINETICS INC
$APLS Apellis Pharmaceuticals, Inc.
$ONCCALL BeOne Medicines Ltd.
$AVTX Avalo Therapeutics, Inc.$ALMSPUT ALUMIS INC.
$SLNO SOLENO THERAPEUTICS INC$LQDAPUT Liquidia Corp
$CNTAPUT Centessa Pharmaceuticals plc
$IDYACALL IDEAYA Biosciences, Inc.$IDYAPUT IDEAYA Biosciences, Inc.
$FDMT 4D Molecular Therapeutics, Inc.
$NXTC NextCure, Inc.
$PALI PALISADE BIO, INC.Browse Top Institutional Investors
13F Pro tracks 8,700+ institutional investors filing 13F reports with the SEC.
to search all 8,700+ institutional filers.
Available Analysis
13F Pro tracks comprehensive institutional data for Exome Asset Management LLC including:
Track Exome Asset Management LLC's Full Portfolio
See every holding, quarter-over-quarter changes, sector allocation, and accumulation patterns for Exome Asset Management LLC and 8,700+ other institutional investors.
Free tier includes full 13F search and fund profiles. Pro starts at $6.67/mo (billed annually).
AI-Powered Hedge Fund Analysis: Exome Asset Management LLC
13F Pro is an AI hedge fund tracker and stock research platform. For Exome Asset Management LLC (SEC CIK: 2011932), the platform ingests every quarterly Form 13F filing and applies AI-powered analysis on top — 10 specialized AI analysts (value, growth, momentum, macro, activist, and more) debate the fund's top positions and publish AI-generated analysis with cited SEC sources.
Every holding in Exome Asset Management LLC's portfolio is scored on a 32-signal AI quality ranking (ROIC, FCF margin, revenue growth, institutional flow, earnings quality, shareholder dilution, and more). Track accumulation and distribution quarter over quarter, identify conviction positions, and see AI stock analysis for each position — alongside 8,700+ other institutional filers and 2,800+ AI-ranked companies.